| Literature DB >> 35740174 |
Andreia Silva1,2, Elisabeth Costa2, Américo Freitas2, Adelaide Almeida1.
Abstract
Urinary tract infections (UTIs) are one of the most common infectious diseases at the community level. The continue misuse of antimicrobials is leading to an increase in bacterial resistance, which is a worldwide problem. The objective of this work was to study the incidence and pattern of antimicrobial resistance of the main bacteria responsible for UTI in the community of central and northern Portugal, and establish an appropriate empirical treatment. The urine samples were collected in Avelab-Laboratório Médico de Análises Clínicas over a period of 5 years (2015-2019). The urine cultures were classified as positive when bacterial growth was equal to or higher than 105 CFU/mL, and only for these cases, an antimicrobial susceptibility test was performed. Of the 106,019 samples analyzed, 15,439 had a urinary infection. Urinary infections were more frequent in females (79.6%) than in males (20.4%), affecting more elderly patients (56.9%). Escherichia coli (70.1%) was the most frequent uropathogen, followed by Klebsiella pneumoniae (8.9%). The bacteria responsible for UTI varied according to the patient's sex, with the greatest differences being observed for Enterococcus faecalis and Pseudomonas aeruginosa, these being more prevalent in men. In general, there was a growth in bacterial resistance as the age of the patients increased. The resistance of bacteria in male patients was, in most cases, statistically different (Chi-Square test, p < 0.05) from that observed for bacteria isolated from female patients, showing, in general, higher resistance in male patients. Although E. coli was the most responsible uropathogen for UTI, it was among the bacteria most susceptible to antibiotics. The isolates of K. pneumoniae, Proteus vulgaris and Enterobacter showed high resistance to the tested antimicrobials. The most common multidrug-resistant (MDR) bacteria implicated in UTI were K. pneumoniae (40.4%) and P. aeruginosa (34.7%), but E. coli, the most responsible bacteria for UTI, showed a MDR of 23.3%. When we compared our results with the results from 10 years ago for the same region, in general, an increase in bacterial resistance was observed. The results of this study confirmed that urinary tract infections are a very common illness, caused frequently by resistant uropathogens, for which the antibiotic resistance profile has varied over a short time, even within a specific region. This indicates that periodically monitoring the microbial resistance of each region is essential in order to select the best empirical antibiotic therapy against these infections, and prevent or decrease the resistance among uropathogenic strains.Entities:
Keywords: antimicrobial resistance; antimicrobials; community acquired infections; urinary tract infection; uropathogens
Year: 2022 PMID: 35740174 PMCID: PMC9220357 DOI: 10.3390/antibiotics11060768
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Incidence of the main bacteria implicated in urinary tract infections during the study period according to age and sex.
| Children | Adolescents | Young Adults | Adults | Elderly | Isolates in the 5 Years (%) 1 | Females | Males | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0–12 Years | 13–18 Years | 19–34 Years | 35–64 Years | >65 Years | ||||||||||||||
| Total 1 | F 2 | M 2 | Total 1 | F 2 | M 2 | Total 1 | F 2 | M 2 | Total 1 | F 2 | M 2 | Total 1 | F 2 | M 2 | ||||
| Bacteria | N = 282 | n = 232 | n = 50 | N = 157 | n = 147 | n = 10 | N = 1277 | n = 1206 | n = 70 | N = 4753 | n = 4044 | n = 709 | N = 8556 | n = 6330 | n = 2226 | |||
|
| 74.8 | 67.4 3 | 7.4 | 63.1 | 59.3 3 | 3.8 | 75.3 | 71.1 3 | 4.2 | 77.1 4 | 67.2 3 | 9.9 | 68.7 | 55.2 3 | 13.5 | 70.1 | 76.2 3 | 55.6 |
|
| 1.8 | 1.1 | 0.7 | 6.4 | 5.8 3 | 0.6 | 4.5 | 4.1 3 | 0.4 | 6.2 | 4.9 3 | 1.3 | 11.7 4 | 8.3 3 | 3.4 | 8.9 | 8.4 | 11.7 3 |
|
| 16.3 4 | 8.9 | 7.4 | 10.2 | 9.6 3 | 0.6 | 5.3 | 5.2 3 | 0.1 | 5.2 | 4.4 3 | 0.8 | 5.5 | 3.0 3 | 2.5 | 5.5 | 5.4 | 6.7 3 |
|
| 1.1 | 0.4 | 0.7 | 0.6 | 0.6 | 0.0 | 0.1 | 0.1 | 0.0 | 0.4 | 0.2 | 0.2 | 1.2 4 | 0.7 | 0.5 | 0.8 | 0.6 | 1.9 |
| 0.0 | 0.0 | 0.0 | 1.3 4 | 1.3 | 0.0 | 0.4 | 0.4 | 0.0 | 0.8 | 0.6 3 | 0.2 | 1.2 | 0.6 | 0.6 | 0.9 | 0.8 | 1.8 3 | |
|
| 0.4 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.3 | 0.2 | 0.1 | 0.5 | 0.4 3 | 0.1 | 1.1 4 | 0.7 3 | 0.4 | 0.8 | 0.7 | 1.3 3 |
|
| 2.1 | 1.8 | 0.4 | 0.0 | 0.0 | 0.0 | 0.2 | 0.1 | 0.1 | 1.3 | 0.3 3 | 1.3 | 4.2 4 | 1.9 | 2.3 | 2.8 | 1.6 | 8.1 3 |
|
| 1.1 | 0.7 | 0.4 | 0.6 | 0.6 | 0.0 | 2.5 | 2.1 3 | 0.4 | 2.1 | 1.2 | 0.9 | 4.1 4 | 1.5 3 | 2.6 | 3.2 | 1.8 | 8.8 3 |
|
| 1.8 | 1.8 | 0.0 | 14.0 4 | 12.7 3 | 1.3 | 7.0 | 6.8 3 | 0.2 | 3.5 | 3.2 3 | 0.3 | 1.2 | 0.4 3 | 0.8 | 2.5 | 2.5 | 2.8 3 |
|
| 0.7 | 0.7 | 0.0 | 3.2 4 | 3.2 | 0.0 | 3.1 | 3.0 3 | 0.1 | 1.3 | 1.3 3 | 0.0 | 0.1 | 0.1 | 0.0 | 0.8 | 1.0 3 | 0.2 |
|
| 0.0 | 0.0 | 0.0 | 0.6 | 0.6 | 0.0 | 1.3 | 1.2 3 | 0.1 | 1.6 4 | 1.4 3 | 0.2 | 1.0 | 0.7 3 | 0.3 | 1.1 | 1.2 3 | 1.1 |
| Total (%) | 1.9 | 1.6 | 0.3 | 1.0 | 0.9 | 0.1 | 8.5 | 8.0 | 0.5 | 31.6 | 26.9 | 4.7 | 56.9 | 42.1 | 14.8 | - | 79.6 | 20.4 |
N: total number of bacteria for each age group; n: total number of bacteria for each sex; 1, percentage determined in relation to N; 2, percentage determined in relation to n; 3, statistically significant differences of frequency between sexes; 4 , statistically significant differences between age groups; M: male; F: female.
Figure 1Incidence of the main bacteria implicated in UTIs by sex during the study period (2015–2019).
Average antimicrobial resistance of the main Gram-negative uropathogens for female and male patients.
| Antimicrobial Group | Antimicrobials |
|
|
|
|
|
| |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % | F | M | N | % | F | M | N | % | F | M | N | % | F | M | N | % | F | M | N | % | F | M | N | % | F | M | |||
| Aminoglycosides | Amikacin | 7246 | 1.6 | 1.5 * | 2.4 | 952 | 3.9 | 3.3 | 5.2 | 573 | 0.7 | 0.6 | 0.0 | 100 | 2.0 | 0.0 | 3.3 | 139 | 4.3 | 2.3 | 7.5 | 104 | 1.9 | 1.4 | 3.1 | 424 | 17.3 | 13.6 | 19.9 | |
| Gentamicin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 425 | 31.1 | 27.9 | 33.3 | ||
| Tobramycin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 416 | 21.2 | 15.5 * | 25.2 | ||
| β-lactam | Carbapenems | Imipenem | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 430 | 15.3 | 17.4 * | 26.0 |
| Cephalosporins (first G) | Cefazolin | 9474 | 14.9 | 13.1 * | 24.7 | 1105 | 39.3 | 31.8 * | 58.6 | 737 | 15.2 | 14.0 | 18.8 | 111 | 100.0 | 100.0 | 100.0 | 125 | 100.0 | 100.0 | 100.0 | 102 | 32.4 | 28.2 | 41.9 | - | - | - | - | |
| Cephalosporins (second G) | Cefuroxime | 10,814 | 10.0 | 8.5 * | 17.9 | 1368 | 33.4 | 26.7 * | 52.2 | 848 | 4.0 | 3.3 | 6.3 | 124 | 100.0 | 100.0 | 100.0 | 144 | 77.8 | 75.6 | 81.5 | 120 | 16.7 | 15.0 | 20.0 | - | - | - | - | |
| Cephalosporins (third G) | Cefotaxime | 10,796 | 7.2 | 6.1 * | 13.2 | 1360 | 28.8 | 22.8 * | 45.7 | 844 | 1.5 | 1.6 | 1.5 | 123 | 4.9 | 4.5 | 5.6 | 142 | 21.1 | 13.5 * | 34.0 | 120 | 12.5 | 10.0 | 17.5 | - | - | - | - | |
| Ceftazidime | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 431 | 26.9 | 24.3 | 28.9 | ||
| Cephalosporins (fourth G) | Cefepime | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 431 | 20.6 | 19.5 | 21.5 | |
| Monobactams | Aztreonam | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 428 | 16.4 | 17.5 | 25.5 | |
| Penicillins | Amoxicillin | 10,816 | 46.3 | 44.1 * | 57.7 | 1366 | 100.0 | 100.0 | 100.0 | 847 | 36.6 | 34.3 * | 43.7 | 124 | 100.0 | 100.0 | 100.0 | 144 | 100.0 | 100.0 | 100.0 | 120 | 100.0 | 100.0 | 100.0 | - | - | - | - | |
| AMX-CLA | 10,807 | 20.3 | 18.8 * | 28.5 | 1365 | 69.4 | 65.7 * | 79.7 | 846 | 9.9 | 7.8 * | 16.6 | 124 | 58.9 | 56.1 | 62.1 | 144 | 100.0 | 100.0 | 100.0 | 120 | 55.0 | 51.3 | 62.5 | - | - | - | - | ||
| PIP-TAZ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 432 | 20.1 | 17.3 | 22.3 | ||
| Quinolones | Ciprofloxacin | 10,489 | 20.5 | 18.0 * | 33.7 | 1351 | 34.6 | 27.8 * | 53.7 | 788 | 21.6 | 18.6 * | 31.0 | 120 | 42.5 | 42.2 | 42.9 | 142 | 21.1 | 11.4 * | 37.0 | 119 | 20.2 | 16.3 | 28.2 | 430 | 44.0 | 39.9 | 47.0 | |
| Miscellaneous agents | Nitrofurantoin | 10,804 | 7.0 | 6.4 * | 10.2 | 1273 | 81.7 | 79.8 * | 86.8 | 843 | 100.0 | 100.0 | 100.0 | 124 | 100.0 | 100.0 | 100.0 | 138 | 73.9 | 72.1 | 76.9 | 113 | 77.9 | 73.7 | 86.5 | - | - | - | - | |
| Fosfomycin | 9829 | 1.4 | 1.4 | 1.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| SXT | 10,811 | 24.8 | 23.3 * | 33.1 | 1365 | 36.5 | 30.4 * | 53.3 | 846 | 28.8 | 28.2 | 30.7 | 124 | 41.9 | 47.0 | 36.2 | 144 | 22.2 | 15.6 * | 33.3 | 120 | 22.5 | 18.8 | 30.0 | - | - | - | - | ||
* Statistically significant differences (p-value < 0.05) of antimicrobial resistance between female and male patients; -, antimicrobial not tested; G, generation.
Average antimicrobial resistance of the main Gram-positive uropathogens for female and male patients.
| Antimicrobial Group | Antimicrobials |
|
|
|
| |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % | F | M | N | % | F | M | N | % | F | M | N | % | F | M | |||
| Aminoglycosides | Gentamicin | 473 | 37.8 | 33.0 | 41.8 | 270 | 4.1 | 2.0 * | 10.4 | - | - | - | - | - | - | - | - | |
| β-lactam | Cephalosporins (third G) | Cefotaxime | - | - | - | - | - | - | - | - | - | - | - | - | 176 | 2.8 | 2.8 | 2.9 |
| Penicillins | Ampicillin | 465 | 7.5 | 8.1 | 7.1 | - | - | - | - | - | - | - | - | 175 | 1.1 | 0.7 | 3.0 | |
| Amoxicillin | 436 | 8.3 | 8.2 | 8.3 | - | - | - | - | 103 | 48.5 | 47.4 | 66.7 | 166 | 2.4 | 2.3 | 3.0 | ||
| AMX-CLA | - | - | - | - | 379 | 11.6 | 6.4 * | 29.8 | 120 | 6.7 | 6.1 | 16.7 | - | - | - | - | ||
| Quinolones | Ciprofloxacin | 485 | 46.4 | 43.1 | 49.1 | 363 | 15.7 | 10.3 * | 33.7 | 114 | 5.3 | 4.7 | 14.3 | - | - | - | - | |
| Levofloxacin | 472 | 38.3 | 29.0 * | 45.8 | - | - | - | - | - | - | - | - | 173 | 7.5 | 7.1 | 9.4 | ||
| Miscellaneous agents | Nitrofurantoin | 470 | 3.2 | 3.3 | 3.1 | 374 | 5.9 | 2.7 * | 17.7 | 120 | 4.2 | 3.5 | 14.3 | 146 | 0.7 | 0.9 | 0.0 | |
| SXT | - | - | - | - | 383 | 14.6 | 9.7 * | 31.8 | 120 | 10.8 | 10.5 | 16.7 | 134 | 39.6 | 38.0 | 46.2 | ||
* Statistically significant differences (p-value < 0.05) of antimicrobial resistance between female and male patients; -, antimicrobial not tested. For E. faecalis, a higher dose of gentamicin was used. G, generation.
Figure 2Variation in the antimicrobial resistance patterns of Gram-negative bacteria during the study period (2015–2019). G, generation.
Figure 3Variation in the antimicrobial resistance patterns of Gram-positive bacteria during the study period. G, generation.
Calculated bacterial resistance to the antimicrobials recommended as first-line therapy for empirical treatment of UTI.
| Resistance to First-Line Therapy | |||||
|---|---|---|---|---|---|
| Bacteria | Incidence | FOM (%) | FOM (%) 1 | NIT (%) | NIT (%) 1 |
|
| 70.1 | 1.4 | 1.0 | 7.0 | 4.9 |
|
| 8.9 | - | - | 81.7 | 7.3 |
|
| 5.5 | - | - | 100.0 | 5.4 |
|
| 3.2 | - | - | 3.2 | 0.1 |
|
| 2.5 | - | - | 5.9 | 0.1 |
|
| 1.1 | - | - | 0.7 | 0.0 |
| 0.9 | - | - | 73.9 | 0.7 | |
|
| 0.8 | - | - | 100.0 | 0.8 |
|
| 0.8 | - | - | 4.2 | 0.0 |
|
| 0.8 | - | - | 77.9 | 0.6 |
| Average (%) | - | - | 1.0 | - | 19.9 |
FOM, fosfomycin; NIT, nitrofurantoin; (%), average resistance; (%) 1, calculated resistance.
Calculated bacterial resistance to the antimicrobials recommended as alternative therapy for empirical treatment of UTI.
| Resistance to Alternative Therapy | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bacteria | Incidence | CEP 1st (%) | CEP 1st (%) 1 | CEP 2nd (%) | CEP 2nd (%) 1 | CEP 3rd (%) | CEP 3rd (%) 1 | QUI (%) | QUI (%) 1 | AMX-CLA (%) | AMX-CLA (%) 1 | SXT (%) | SXT (%) 1 |
|
| 70.1 | 14.9 | 10.4 | 10.0 | 7.0 | 7.2 | 5.0 | 20.5 | 14.4 | 20.3 | 14.2 | 24.8 | 17.4 |
|
| 8.9 | 39.3 | 3.5 | 33.4 | 3.3 | 28.8 | 2.6 | 34.6 | 3.1 | 69.4 | 6.2 | 36.5 | 3.2 |
|
| 5.5 | 15.2 | 0.8 | 4.0 | 0.2 | 1.5 | 0.0 | 21.6 | 1.2 | 9.9 | 0.5 | 28.8 | 1.6 |
|
| 3.2 | - | - | - | - | - | - | 42.4 | 1.4 | - | - | - | - |
|
| 2.8 | - | - | - | - | - | - | 44.0 | 1.2 | - | - | - | - |
|
| 2.5 | - | - | - | - | - | - | 15.7 | 0.4 | 11.6 | 0.3 | 14.6 | 0.4 |
|
| 1.1 | - | - | - | - | 2.8 | 0.0 | 7.5 | 0.1 | - | - | 39.6 | 0.4 |
| 0.9 | 100.0 | 0.9 | 77.8 | 0.7 | 21.1 | 0.2 | 21.1 | 0.2 | 100.0 | 0.9 | 22.2 | 0.2 | |
|
| 0.8 | 100.0 | 0.8 | 100.0 | 0.8 | 4.9 | 0.0 | 42.5 | 0.3 | 58.9 | 0.5 | 41.9 | 0.3 |
|
| 0.8 | - | - | - | - | - | - | 5.3 | 0.0 | 6.7 | 0.1 | 10.8 | 0.1 |
|
| 0.8 | 32.4 | 0.3 | 16.7 | 0.1 | 12.5 | 0.1 | 20.2 | 0.2 | 55.0 | 0.4 | 22.5 | 0.2 |
| Average (%) | - | - | 16.7 | - | 12.1 | - | 7.9 | - | 22.5 | - | 23.1 | - | 23.8 |
CEP, cephalosporin; QUI, quinolones; AMX-CLA, amoxicillin and clavulanic acid; SXT, trimethoprim-sulfamethoxazole; (%), average resistance; (%) 1, calculated resistance.
Percentage of multidrug resistance in the studied bacteria.
| Bacteria in UTI | % of MDR Isolates |
|---|---|
|
| 23.3 |
|
| 40.4 |
|
| 10.0 |
|
| 19.4 |
| 29.9 | |
|
| 24.2 |
|
| 34.7 |
|
| 18.3 |
|
| 5.8 |
|
| 6.8 |